AU2017345468B2 - Bromodomain inhibitor - Google Patents

Bromodomain inhibitor Download PDF

Info

Publication number
AU2017345468B2
AU2017345468B2 AU2017345468A AU2017345468A AU2017345468B2 AU 2017345468 B2 AU2017345468 B2 AU 2017345468B2 AU 2017345468 A AU2017345468 A AU 2017345468A AU 2017345468 A AU2017345468 A AU 2017345468A AU 2017345468 B2 AU2017345468 B2 AU 2017345468B2
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
compound
methylisoquinolin
methylsulfonylphenyl
cyclopropylmethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017345468A
Other languages
English (en)
Other versions
AU2017345468A1 (en
Inventor
Juan Manuel Betancort
Jeffrey Alan Stafford
Ryan STANSFIELD
James Marvin Veal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Quanticel Research Inc
Original Assignee
Celgene Quanticel Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Research Inc filed Critical Celgene Quanticel Research Inc
Publication of AU2017345468A1 publication Critical patent/AU2017345468A1/en
Assigned to CELGENE QUANTICEL RESEARCH, INC. reassignment CELGENE QUANTICEL RESEARCH, INC. Amend patent request/document other than specification (104) Assignors: CELGENE QUANTICEL RESEARCH, INC
Application granted granted Critical
Publication of AU2017345468B2 publication Critical patent/AU2017345468B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2017345468A 2016-10-20 2017-10-19 Bromodomain inhibitor Active AU2017345468B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662410756P 2016-10-20 2016-10-20
US62/410,756 2016-10-20
PCT/US2017/057439 WO2018075796A1 (en) 2016-10-20 2017-10-19 Bromodomain inhibitor

Publications (2)

Publication Number Publication Date
AU2017345468A1 AU2017345468A1 (en) 2019-06-06
AU2017345468B2 true AU2017345468B2 (en) 2022-06-02

Family

ID=62019669

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017345468A Active AU2017345468B2 (en) 2016-10-20 2017-10-19 Bromodomain inhibitor

Country Status (7)

Country Link
EP (1) EP3528810A4 (zh)
JP (3) JP7129973B2 (zh)
CN (1) CN110099685A (zh)
AR (1) AR109859A1 (zh)
AU (1) AU2017345468B2 (zh)
TW (1) TW201821062A (zh)
WO (1) WO2018075796A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201642860A (zh) * 2015-04-22 2016-12-16 塞爾基因定量細胞研究公司 布羅莫結構域抑制劑
US10702517B2 (en) 2015-04-22 2020-07-07 Celgene Quanticel Research, Inc. Bromodomain inhibitor
US11566004B2 (en) * 2018-07-23 2023-01-31 Celgene Quanticel Research, Inc. Process for the preparation of bromodomain inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150111885A1 (en) * 2013-10-18 2015-04-23 Quanticel Pharmaceuticals Bromodomain inhibitors
WO2016172618A1 (en) * 2015-04-22 2016-10-27 Celgene Quanticel Research, Inc. Bromodomain inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2396079A1 (en) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
US20160158246A1 (en) * 2013-08-06 2016-06-09 Oncoethix Gmbh Method of treating diffuse large b-cell lymphoma (dlbcl) using a bet-bromodomain inhibitor
CN105873577B (zh) * 2013-08-30 2019-06-18 西奈山伊坎医学院 环插烯酰胺作为溴结构域抑制剂
US9757385B2 (en) 2013-11-27 2017-09-12 Merck Sharp & Dohme Corp. Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds
CN105732624B (zh) * 2016-01-28 2019-08-02 中国药科大学 吡咯[4,3,2-de]喹啉-2(1H)-酮类BRD4蛋白抑制剂的制备方法及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150111885A1 (en) * 2013-10-18 2015-04-23 Quanticel Pharmaceuticals Bromodomain inhibitors
WO2016172618A1 (en) * 2015-04-22 2016-10-27 Celgene Quanticel Research, Inc. Bromodomain inhibitor

Also Published As

Publication number Publication date
AU2017345468A1 (en) 2019-06-06
EP3528810A1 (en) 2019-08-28
JP7129973B2 (ja) 2022-09-02
AR109859A1 (es) 2019-01-30
TW201821062A (zh) 2018-06-16
EP3528810A4 (en) 2020-06-17
WO2018075796A1 (en) 2018-04-26
JP2024056905A (ja) 2024-04-23
CN110099685A (zh) 2019-08-06
JP2022095897A (ja) 2022-06-28
JP2019535671A (ja) 2019-12-12

Similar Documents

Publication Publication Date Title
CA2983446C (en) Bromodomain inhibitor
JP2024056905A (ja) ブロモドメイン阻害剤
CN113226302B (zh) 用于治疗或预防痛风或高尿酸血症的化合物的晶型
US20230301983A1 (en) Bromodomain inhibitor
CA3140412A1 (en) Compound for treating gout or hyperuricemia
CA3121624A1 (en) Methods for treating or preventing gout or hyperuricemia
WO2023098872A1 (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia
JP2020532522A (ja) 感覚有毛細胞死を予防または処置するための化合物の結晶形態
US20240010654A1 (en) Crystalline forms of a tyk2 inhibitor
EA043666B1 (ru) Кристаллические формы соединения для лечения или профилактики подагры или гиперурикемии

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: CELGENE QUANTICEL RESEARCH, INC.

Free format text: FORMER NAME(S): CELGENE QUANTICEL RESEARCH, INC

FGA Letters patent sealed or granted (standard patent)